Virchows Archiv

, Volume 449, Issue 1, pp 24–30 | Cite as

Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer

  • Walter SchippingerEmail author
  • Peter Regitnig
  • Nadia Dandachi
  • Klaus-Dieter Wernecke
  • Thomas Bauernhofer
  • Hellmut Samonigg
  • Farid Moinfar
Original Article


The purpose of this study was to investigate the influence of androgen receptor (AR) expression in tumour tissue on survival of patients with metastatic breast cancer. Tumour specimens from 232 patients with metastatic breast cancer were examined for presence of AR by immunohistochemistry. According to the extent of immunostaining, AR expression was classified as score 0, 1+, 2+, or 3+. AR positivity was observed in 164 (70.7%) tumours. The median survival after disease recurrence (SAR) of patients with AR-expressing tumours was significantly longer compared to that of patients with AR-negative tumours (21.89 months, 95% CI 17.23–26.55 vs 11.99 months, 95% CI 9.36–14.62; log-rank test 0.0282). In addition, patients with AR score 3+ had a significantly longer disease-free survival (DFS) compared to patients with AR score 0, 1+, and 2+, (24.67 months, 95% CI 13.72–35.62 vs 16.36 months, 95% CI 13.18–19.54, log-rank test 0.0043). Multivariate Cox analyses showed no statistically significant influence of AR expression on DFS or SAR. In conclusion, SAR is significantly longer in patients with AR-expressing breast carcinoma. However, AR expression is not an independent prognostic factor for SAR in metastatic breast cancer.


Metastatic breast cancer Androgen receptor Prognostic factors 


  1. 1.
    Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ (2003) Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 120:725–731PubMedCrossRefGoogle Scholar
  2. 2.
    Allemani C, Sant M, Berrino F, Aareleid T, Chaplain G, Coebergh JW, Colonna M, Contiero P, Danzon A, Federico M (2004) Prognostic value of morphology and hormone receptor status in breast cancer—a population-based study. Br J Cancer 91:1263–1268PubMedCrossRefGoogle Scholar
  3. 3.
    Brentani MM, Franco EL, Oshima CT, Pacheco MM (1986) Androgen, estrogen, and progesterone receptor levels in malignant and benign breast tumors: a multivariate analysis approach. Int J Cancer 38:637–642PubMedCrossRefGoogle Scholar
  4. 4.
    Britton JA, Gammon MD, Schoenberg JB, Stanford JL, Coates RJ, Swanson CA, Potischman N, Malone KE, Brogan DJ, Daling JR (2002) Risk of breast cancer classified by joint estrogen receptor and progesterone receptor status among women 20–44 years of age. Am J Epidemiol 156:507–516PubMedCrossRefGoogle Scholar
  5. 5.
    Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ (1984) Androgen receptors in breast cancer. Cancer 54:2436–2440PubMedCrossRefGoogle Scholar
  6. 6.
    Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM (2003) Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97:545–553PubMedCrossRefGoogle Scholar
  7. 7.
    Clark GM, Sledge GW Jr, Osborne CK, McGuire WL (1987) Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5:55–61PubMedGoogle Scholar
  8. 8.
    Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRefGoogle Scholar
  9. 9.
    Hahnel R, Woodings T, Vivian AB (1979) Prognostic value of estrogen receptors in primary breast cancer. Cancer 44:671–675PubMedCrossRefGoogle Scholar
  10. 10.
    Howell A, Barnes DM, Harland RN, Redford J, Bramwell VH, Wilkinson MJ, Swindell R, Crowther D, Sellwood RA (1984) Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet 1:588–591PubMedCrossRefGoogle Scholar
  11. 11.
    Isola JJ (1993) Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 170:31–35PubMedCrossRefGoogle Scholar
  12. 12.
    Knight WA, Livingston RB, Gregory EJ, McGuire WL (1977) Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37:4669–4671PubMedGoogle Scholar
  13. 13.
    Kuenen-Boumeester V, Van der Kwast TH, Claassen CC, Look MP, Liem GS, Klijn JG, Henzen-Logmans SC (1996) The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 32A:1560–1565PubMedCrossRefGoogle Scholar
  14. 14.
    Miller WR, Telford J, Dixon JM, Hawkins RA (1985) Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity. Eur J Cancer Clin Oncol 21:539–542PubMedCrossRefGoogle Scholar
  15. 15.
    Moinfar F, Okcu M, Tsybrovskyy O, Regitnig P, Lax SF, Weybora W, Ratschek M, Tavassoli FA, Denk H (2003) Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 98:703–711PubMedCrossRefGoogle Scholar
  16. 16.
    Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Corgnati A, Sperotto L, Recaldin E, Spagnolli P, Manfrin E (1997) Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 45:241–249PubMedCrossRefGoogle Scholar
  17. 17.
    Perrault DJ, Logan DM, Stewart DJ, Bramwell VH, Paterson AH, Eisenhauer EA (1988) Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs 6:207–210PubMedCrossRefGoogle Scholar
  18. 18.
    Riva C, Dainese E, Caprara G, Rocca PC, Massarelli G, Tot T, Capella C, Eusebi V (2005) Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma. Virchows Arch 447:695–700PubMedCrossRefGoogle Scholar
  19. 19.
    Soreide JA, Lea OA, Varhaug JE, Kvinnsland S (1992) Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol 18:112–118PubMedGoogle Scholar
  20. 20.
    Stanford JL, Szklo M, Brinton LA (1986) Estrogen receptors and breast cancer. Epidemiol Rev 8:42–59PubMedGoogle Scholar
  21. 21.
    Wittliff JL (1974) Specific receptors of the steroid hormones in breast cancer. Semin Oncol 1:109–118PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Walter Schippinger
    • 1
    Email author
  • Peter Regitnig
    • 2
  • Nadia Dandachi
    • 1
  • Klaus-Dieter Wernecke
    • 3
  • Thomas Bauernhofer
    • 1
  • Hellmut Samonigg
    • 1
  • Farid Moinfar
    • 2
  1. 1.Division of Oncology, Department of Internal MedicineMedical University of GrazGrazAustria
  2. 2.Institute of PathologyMedical University GrazGrazAustria
  3. 3.Institute of Medical BiometryHumboldt University of BerlinBerlinGermany

Personalised recommendations